IN Brief:
- The India–EU free trade agreement is expected to increase cross-border movement in pharmaceuticals, automotive components, chemicals, machinery, and technology.
- Pharma exports will place greater pressure on temperature control, validated packaging, documentation, and shipment predictability.
- Automotive and industrial supply chains are likely to reassess sourcing, inventory, and regional logistics networks as market access improves.
The European Union and India are moving towards a free trade agreement that could reshape logistics demand across pharmaceuticals, automotive components, chemicals, engineering goods, machinery, and technology.
The agreement is targeted for implementation in 2027 and is expected to progressively reduce tariffs, simplify customs procedures, and improve shipment predictability between the two markets. Goods trade between India and the EU has grown strongly over the past decade, with the EU becoming India’s third-largest trading partner in 2025 and India ranking as the EU’s ninth-largest trading partner.
Pharmaceuticals are likely to be among the earliest sectors affected. India’s pharmaceutical industry ranks third globally by volume and eleventh by value, supported by more than 3,000 companies and 10,500 manufacturing units. Pharmaceutical exports from India grew by 9.4% to $30.47bn in FY2024–25, with Europe remaining an important destination market.
Higher pharma volumes would place more pressure on temperature-controlled transport, validated packaging, GDP-aligned processes, customs accuracy, batch traceability, and reliable air and ocean capacity. Reduced tariff friction can increase trade, but healthcare products still move inside a high-control logistics environment where delay, temperature excursion, or documentation failure can quickly turn into a costly exception.
Automotive supply chains are another major area of exposure. India is already an important production and sourcing base for components, engineering goods, and finished vehicles. Improved market access into Europe could encourage more component exports, supplier integration, and production-linked trade flows, while European manufacturers may reassess sourcing strategies where India can offer capacity, technical capability, and a hedge against overconcentration in other regions.
The logistics requirement is likely to be broader than additional freight capacity. Automotive flows depend on sequencing, packaging return loops, supplier visibility, inventory buffers, and reliable handover between plants, ports, and consolidation centres. As sourcing strategies change, customs planning, packaging specifications, port selection, and transport lead times will need to be aligned earlier in the commercial process.
The trade deal also lands against a freight network that is still dealing with operational strain. Indian transport delays are already threatening freight schedules, exposing the gap that can sit between trade ambition and freight execution. Increased export demand will strengthen the case for better corridor planning, stronger multimodal links, and more predictable inland transport into major ports and airports.
Europe’s position requires the same level of operational caution. The agreement could support diversification away from more politically exposed sourcing routes, but it may also deepen dependence on Indian pharma and industrial inputs. Lower tariffs and smoother customs processes are attractive, yet buyers will still need assurance around redundancy, quality control, regulatory compliance, and lead-time reliability.
The most immediate logistics gains are likely to come from companies already operating across both regions. Established pharma manufacturers, automotive suppliers, freight forwarders, cold chain specialists, and contract logistics providers will be best placed to convert policy change into operational advantage. New entrants may face a steeper learning curve around compliance, product classification, documentation, and lane reliability.
Logistics technology will also sit closer to the centre of trade execution. Better market access creates more shipment volume, but it also creates more classification, documentation, duty management, and supplier coordination work. Digital freight platforms, customs tools, and visibility systems will need to support the full chain of compliance events from supplier dispatch to final delivery.
India–EU trade will not be transformed by tariff reduction alone. The practical shift will come from whether logistics networks can absorb more regulated, high-value, and time-sensitive goods without weakening reliability. In pharma and automotive, the deal creates opportunity, but the operational test will sit in cold chain control, customs discipline, inland transport, and predictable movement between two large, complex markets.